Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
about
Rho GTPases: Novel Players in the Regulation of the DNA Damage Response?Neuregulin-1/erbB activities with focus on the susceptibility of the heart to anthracyclinesTherapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathyMitochondrial Calpain-1 Disrupts ATP Synthase and Induces Superoxide Generation in Type 1 Diabetic Hearts: A Novel Mechanism Contributing to Diabetic CardiomyopathyCancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes.ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity.Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma TreatmentHSP25 down-regulation enhanced p53 acetylation by dissociation of SIRT1 from p53 in doxorubicin-induced H9c2 cell apoptosis.Ataxia telangiectasia mutated in cardiac fibroblasts regulates doxorubicin-induced cardiotoxicity.Paeoniflorin inhibits doxorubicin-induced cardiomyocyte apoptosis by downregulating microRNA-1 expression.The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling.Ascorbate attenuates pulmonary emphysema by inhibiting tobacco smoke and Rtp801-triggered lung protein modification and proteolysis.Anthracycline Chemotherapy and Cardiotoxicity.Novel aspects of ROS signalling in heart failure.Cytotoxin-induced NADPH oxides activation: roles in regulation of cell death.Rac1-mediated cardiac damage causes diastolic dysfunction in a mouse model of subacute doxorubicin-induced cardiotoxicity.Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.Oxidative stress does not play a primary role in the toxicity induced with clinical doses of doxorubicin in myocardial H9c2 cells.Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity.Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.Pleiotropic Effects of Statins on the Cardiovascular System.The epigenetic landscape related to reactive oxygen species formation in the cardiovascular system.Rac1 GTPase, a multifunctional player in the regulation of genotoxic stress response.Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity.Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology.Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway.Inflammation leads through PGE/EP3 signaling to HDAC5/MEF2-dependent transcription in cardiac myocytes.
P2860
Q26782005-15DDDBAF-C3B4-491F-BDE1-B6727A375A29Q27022965-12157429-8998-4F3E-9B44-5B5C2190A5F2Q28391746-482D6360-21E6-41F6-8C8E-AC0F029F361BQ28397064-2C389B11-3593-4E9C-8201-DD79D8170E27Q30426853-485BCE70-A34B-4C51-96B2-560850D4A332Q33712788-EC59F689-8A4A-41AF-B660-185D37F26E18Q36339400-3110A68C-2194-4169-8A91-6C1E6D6A9B7EQ36665092-09573205-A0D7-4729-B524-6183B4F6D453Q36674093-18214DBE-568B-4F7E-A9BE-D220435037CFQ36702443-6F93331A-4DB6-4880-A6DE-DA1C307F07DEQ36953530-43D7F353-AEB8-4EF4-B481-B21C77876589Q36974840-25372A29-9CEF-48F1-8E04-52272BF0947AQ37126606-6B30A866-5083-490B-B4D9-032AEC14B106Q37694541-89D6B5BD-E948-4FAF-9A43-CBD4C57B4D27Q38112350-AC668622-6648-4208-945D-90E39FAA7B77Q38359204-9949D68D-891D-4D61-9BB4-8B8C43C4A1E9Q38678046-8D3E9937-6EE6-4BFD-A991-5E1398DB5E5DQ38717558-253B4746-A99D-4338-9263-53005DD819FAQ38797529-62D67346-01E0-4941-998E-ABB23FAFCDE5Q38826619-C766A59E-01FD-40CB-BC60-D178DA5F3C41Q39012650-53B45592-E623-466D-A248-9E92B4C30792Q39069187-C5DE7B8B-E9A1-4541-829B-9A7BBE9AFCCAQ39195350-146F4019-E7A3-49BF-95D2-CB0908F5D4F8Q42790848-2D406238-C092-4C84-A1C2-868B0195366FQ46309853-47792B13-B9AE-4287-9D25-4CFBF9BEE820Q48245077-5A8B5662-DDBE-4209-9285-DB7D405D6655Q50060140-A478492E-DD56-4EC7-BF34-154315BAFF89Q53661913-795DBD1A-9A20-4567-90B5-C88AF6C3F1A6Q54978987-838F4F37-CDFF-4E6F-A9F7-C8C49192524FQ55625734-F5673E8A-88A8-4842-9A49-01B647E847DB
P2860
Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Rac1 signalling mediates doxor ...... ent and -independent pathways.
@en
Rac1 signalling mediates doxor ...... ent and -independent pathways.
@nl
type
label
Rac1 signalling mediates doxor ...... ent and -independent pathways.
@en
Rac1 signalling mediates doxor ...... ent and -independent pathways.
@nl
prefLabel
Rac1 signalling mediates doxor ...... ent and -independent pathways.
@en
Rac1 signalling mediates doxor ...... ent and -independent pathways.
@nl
P2093
P2860
P356
P1476
Rac1 signalling mediates doxor ...... ent and -independent pathways.
@en
P2093
P2860
P356
10.1093/CVR/CVS309
P577
2012-10-01T00:00:00Z